Free Trial
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

Supernus Pharmaceuticals logo
$32.85 -0.12 (-0.36%)
Closing price 04:00 PM Eastern
Extended Trading
$32.87 +0.02 (+0.06%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Key Stats

Today's Range
$32.51
$33.41
50-Day Range
$31.16
$33.96
52-Week Range
$27.05
$40.28
Volume
540,341 shs
Average Volume
698,889 shs
Market Capitalization
$1.84 billion
P/E Ratio
29.59
Dividend Yield
N/A
Price Target
$36.00
Consensus Rating
Hold

Company Overview

Supernus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

SUPN MarketRank™: 

Supernus Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat, and ranked 722nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Supernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Supernus Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Supernus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Supernus Pharmaceuticals is 29.59, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Supernus Pharmaceuticals is 29.59, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.90.

  • Price to Book Value per Share Ratio

    Supernus Pharmaceuticals has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Supernus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.25% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently increased by 21.59%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Supernus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Supernus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.25% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently increased by 21.59%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Supernus Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Supernus Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    2 people have searched for SUPN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

SUPN Stock Analysis - Frequently Asked Questions

Supernus Pharmaceuticals' stock was trading at $36.16 at the beginning of 2025. Since then, SUPN stock has decreased by 9.2% and is now trading at $32.85.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its quarterly earnings results on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. The firm's quarterly revenue was up 14.2% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of Supernus Pharmaceuticals include Wedge Capital Management L L P NC (0.13%), Campbell Newman Asset Management Inc. (0.08%), State of Alaska Department of Revenue (0.06%) and QRG Capital Management Inc. (0.03%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola and Jonathan Rubin.
View institutional ownership trends
.

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
11/04/2024
Today
7/24/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SUPN
CIK
1356576
Employees
580
Year Founded
N/A

Price Target and Rating

High Price Target
$36.00
Low Price Target
$36.00
Potential Upside/Downside
+9.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.11
Trailing P/E Ratio
29.59
Forward P/E Ratio
13.80
P/E Growth
N/A
Net Income
$73.86 million
Net Margins
9.27%
Pretax Margin
13.74%
Return on Equity
12.23%
Return on Assets
9.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.44
Quick Ratio
2.26

Sales & Book Value

Annual Sales
$668.00 million
Price / Sales
2.75
Cash Flow
$4.15 per share
Price / Cash Flow
7.91
Book Value
$18.76 per share
Price / Book
1.75

Miscellaneous

Outstanding Shares
55,990,000
Free Float
51,063,000
Market Cap
$1.84 billion
Optionable
Optionable
Beta
0.70

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:SUPN) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners